1. Home
  2. AGEN vs MSLE Comparison

AGEN vs MSLE Comparison

Compare AGEN & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.93

Market Cap

178.2M

Sector

Health Care

ML Signal

HOLD

MSLE

Satellos Bioscience Inc. Common Stock

N/A

Current Price

$7.68

Market Cap

146.9M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
AGEN
MSLE
Founded
1994
N/A
Country
United States
Canada
Employees
N/A
17
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
178.2M
146.9M
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
AGEN
MSLE
Price
$3.93
$7.68
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$14.50
N/A
AVG Volume (30 Days)
1.0M
65.5K
Earning Date
05-11-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
100.00
N/A
EPS
N/A
N/A
Revenue
$42,877,086.00
N/A
Revenue This Year
$107.63
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.89
N/A
Revenue Growth
89.95
N/A
52 Week Low
$2.63
$5.50
52 Week High
$7.34
$13.39

Technical Indicators

Market Signals
Indicator
AGEN
MSLE
Relative Strength Index (RSI) 49.56 49.08
Support Level $2.96 $6.67
Resistance Level $4.58 $8.37
Average True Range (ATR) 0.42 0.72
MACD -0.03 0.31
Stochastic Oscillator 37.53 50.75

Price Performance

Historical Comparison
AGEN
MSLE

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

About MSLE Satellos Bioscience Inc. Common Stock

Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Share on Social Networks: